CJC-1295
CJC-1295 • Also called CJC 1295
CJC-1295 remains in limbo after its referral to PCAC, leaving clinics with interest but little dependable compounding access.
Current status
Under Review
Growth-hormone-related interest, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Yes
The under-review state is better than outright Category 2 treatment, but it is not the same as legal availability.
Primary Use
Growth-hormone-related interest
Also searched as
CJC 1295
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 19, 2024
Current status signal recorded: Moved into the PCAC review queue..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when CJC-1295 status changes
State-specific notes
Texas
Clinics monitor it closely but sourcing remains inconsistent.